Log In Get Started
Insider Trading April 1, 2026 05:22 PM

Processa Pharmaceuticals director buys $5,252 of PCSA stock, increases direct holding

Director Geraldine Pannu acquires 2,072 shares as company advances a Phase 2 interim analysis

By Derek Hwang PCSA
Processa Pharmaceuticals director buys $5,252 of PCSA stock, increases direct holding
PCSA

A Processa Pharmaceuticals director purchased 2,072 shares on March 31, 2026, for $2.535 each, adding $5,252 to her direct stake as the company progresses a Phase 2 study and shows mixed recent stock performance. The transaction was disclosed in a Form 4 filing and follows recent clinical enrollment milestones.

Key Points

  • Director Geraldine Pannu bought 2,072 shares at $2.535 on March 31, 2026, totaling $5,252.
  • After the purchase Pannu directly holds 2,188 shares; PCSA trades at $2.60, up 9.78% over the past week but down 75% over the past year.
  • Processa completed enrollment and dosing of 20 patients for an interim analysis in its Phase 2 NGC-Cap study comparing PCS6422 plus capecitabine to capecitabine alone.

Geraldine Pannu, a member of the board of directors at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), reported a direct purchase of 2,072 shares of the company's common stock at a price of $2.535 per share, for a total consideration of $5,252. The trade, recorded on a Form 4 filed with the Securities and Exchange Commission, took place on March 31, 2026.

Following the transaction, Pannu's direct ownership in Processa increased to 2,188 shares. At the time of reporting, the stock is trading at $2.60, reflecting a 9.78% gain over the last week, while the company’s share price remains down 75% over the past year.

Processa Pharmaceuticals carries a market capitalization of $6.97 million. According to an InvestingPro analysis cited in company reporting, the firm's balance sheet shows more cash than debt, and the analysis provides 11 additional ProTips for investors in PCSA.

Clinical update

On the clinical front, Processa has completed enrollment and dosing of 20 patients for an interim analysis in its Phase 2 study evaluating NGC-Cap in advanced or metastatic breast cancer. The regimen being studied combines PCS6422 and capecitabine and is being compared against standard capecitabine monotherapy.

The trial cohort consists of patients who have received at least one prior line of therapy; the median number of previous treatments among participants ranges from two to three regimens. Completion of enrollment and dosing for the interim analysis represents a key operational milestone for the company’s ongoing research program.

Implications and context

  • This insider purchase is a direct acquisition disclosed by a company director via SEC filing.
  • Market performance is mixed in the short term with weekly gains but a significant year-over-year decline.
  • Clinical progress includes completion of dosing for an interim analysis in a Phase 2 breast cancer study.

Note on additional resources

The company’s profile and balance-sheet characterization referenced the InvestingPro analysis, which includes the stated ProTips for PCSA investors.

Risks

  • Significant share-price decline over the past year - market and investor sentiment in the biotech sector could affect PCSA.
  • Clinical trial outcomes remain pending - the Phase 2 interim analysis results are uncertain and will influence development prospects.
  • Small market capitalization and limited public float - liquidity and volatility risks for investors in small-cap biotech names.

More from Insider Trading

Monolithic Power Counsel Sells $11.7M in Shares as Stock Nears 52-Week High Apr 10, 2026 Aqua Capital Increases Energizer (ENR) Stake with $251K Purchase Apr 10, 2026 Vicor Chairman Disposes $4.67M in Shares Amid Strong Stock Run Apr 10, 2026 Trio-Tech Director Sells $27,120 in Stock Amid Company Cybersecurity Disclosure and New Orders Apr 10, 2026 Japan Post Reduces Aflac Stake with $18.6 Million Disposal Apr 10, 2026